Diabetes and metabolic disease research
5 European H2020 organizations list this as part of their work — 5 as their primary capability.
Most active in this area
- UNIVERSITE LIBRE DE BRUXELLES
Major Belgian research university strong in diabetes research, theoretical physics, graphene, climate science, and political economy with exceptional EU project coordination capacity.
“Leads T2DSystems on type 2 diabetes systems biomedicine, participates in INNODIA (type 1 diabetes biomarkers/clinical trials) and RHAPSODY (prediabetes risk assessment).”
PrimaryBE130 projects - HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
German research powerhouse in diabetes, metabolic disease, biomedical imaging, and AI-driven omics with 678 partners across 45 countries.
“Core theme across INNODIA (type 1 diabetes biomarkers), HypoFlam (hypothalamic inflammation in obesity/diabetes), DYNAHEALTH, Foie Gras (fatty liver), and multiple ERC grants on metabolism and adipose tissue.”
PrimaryDE97 projects - REGION HOVEDSTADEN
Denmark's Capital Region health authority contributing hospital-based clinical trials, patient registries, and biomarker research across cardiovascular, neuropsychiatric, and metabolic diseases.
“Projects INNODIA (type 1 diabetes biomarkers/clinical trials), DYNAHEALTH (glucose homeostasis), and multiple recent projects focusing on diabetes biomarkers and prevention.”
PrimaryDK79 projects - CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
Spain's national biomedical research consortium linking clinical networks in diabetes, rare diseases, psychiatry, and cardiovascular medicine across 49 countries.
“Core focus spanning T2DSystems, DRIVE, CARDIATEAM, DIABFRAIL-LATAM, STOP, Eat2beNICE, and TREATMENT — covering type 2 diabetes, diabetic cardiomyopathy, and metabolic side effects of psychiatric drugs.”
PrimaryES26 projects - SIB SWISS INSTITUTE OF BIOINFORMATICS
Switzerland's national bioinformatics center providing computational biology, FAIR data platforms, and multi-omics analysis for European health research consortia.
“Consistent engagement across RHAPSODY, BEAt-DKD, Hypo-RESOLVE, CARDIATEAM, and SOPHIA covering type 2 diabetes, diabetic kidney disease, cardiomyopathy, and obesity.”
PrimaryCH23 projects